Sotatercept, an activin-signalling inhibitor, is a promising add-on treatment for patients with advanced pulmonary arterial hypertension (PAH) and a high risk of death who are already receiving the maximum-tolerated dose of background therapy. This finding from the phase III ZENITH trial was presented at the ACC.25 Scientific Sessions and published in The New England Journal of Medicine.

PAH is a progressive, potentially fatal disease characterized by increased blood pressure in the lungs. Its pathobiology features pulmonary vasculature remodelling and culminates in right ventricular failure and death. Available therapies improve pulmonary haemodynamics, exercise capacity and progression-free survival, but the high morbidity and mortality associated with the disease underscore a need for more effective treatment options.